← Leaderboards
Holly Elizabeth Rawizza
Brigham And Women'S Hospital
$3,045,812
Attributed
$3,423,649
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $724.6K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,423,649 · 5
By mechanism
R01$1,692,020 · 2
K23$1,039,709 · 1
R21$691,920 · 2
Top collaborators
- Barry Ryan Lutz2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Hamid Band$15,640,616
- Pamela Vivian Tran$4,737,119
- Vijay K Kuchroo$71,617,613
- Jerrold R. Turner$27,789,454
- Daniel F Dwyer$2,658,193
Others in their field
Top investigators on “Nigeria”
- William Albert Blattner · University Of Maryland Baltimore$216,422,779
- Patrick Dakum · Institute Of Human Virology$46,871,591
- Robert F Garry · Scripps Research Institute, The$26,056,895
- Margaret A Pericak-Vance · Doheny Eye Institute$20,572,172
- Bolanle Oyeledun · Centre For Integrated Health Programs$18,648,374
- Clement Adebayo Adebamowo · University Of Ibadan$16,856,483
Research focus
NigeriaChildChildhoodAdultCaringDesignPublic HealthCountryRecommendationCohortLopinavir/RitonavirPediatric Human Immunodeficiency VirusTuberculosis TreatmentProgramsRifabutinDrug KineticsRifampinTreatment OutcomeProspectiveSafetyTreatment ProtocolsTuberculosisImproved OutcomeRegimen
Grant awards (17)
Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientists$418,170
R01 · FY2025 · AI · contact PI
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention$190,326
R01 · FY2025 · HD · contact PI
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention$66,240
R01 · FY2025 · HD · contact PI
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention$49,912
R01 · FY2025 · HD · contact PI
Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientists$337,504
R01 · FY2024 · AI · contact PI
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention$307,054
R01 · FY2023 · HD · contact PI
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention$322,814
R01 · FY2022 · HD · contact PI
Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use$198,211
R21 · FY2022 · AI · contact PI
Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use$180,339
R21 · FY2021 · AI · contact PI
Rifabutin pharmacokinetics and safety among HIV/TB coinfected infants receiving lopinavir$152,745
R21 · FY2021 · AI · contact PI
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children$59,008
K23 · FY2021 · AI · contact PI
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children$198,504
K23 · FY2020 · AI · contact PI
Rifabutin pharmacokinetics and safety among HIV/TB coinfected infants receiving lopinavir$160,625
R21 · FY2020 · AI · contact PI
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children$198,504
K23 · FY2019 · AI · contact PI
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children$198,932
K23 · FY2018 · AI · contact PI
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children$199,549
K23 · FY2017 · AI · contact PI
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children$185,212
K23 · FY2016 · AI · contact PI